DRUG — BRIGHT MINDS BIOSCIENCES INC

Ownership history in BRAIDWELL LP  ·  2 quarters on record

This page tracks every 13F SEC filing in which BRAIDWELL LP reported a position in BRIGHT MINDS BIOSCIENCES INC (DRUG). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.81% (2025 Q4)
Avg. % of fund
0.68%
First filed
2025 Q3
Last filed
2025 Q4
Quarters held
2
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 ADDED 324,358 +20,673 +6.8% 0.81% $25.3M $78.04
2025 Q3 INITIATED 303,685 — — 0.55% $18.4M $60.66
% of Fund (quarterly)    DRUG price (monthly, adj. close)

Other funds also holding DRUG

As of 2025 Q4 — sorted by position size

ACUTA CAPITAL PARTNERS, LLC 3Y 7Y 4.48% Cormorant Asset Management, LP 3Y 7Y 3.82% Vivo Capital, LLC 3Y 7Y 2.53% MPM BioImpact LLC 3Y 2.06% SUPERSTRING CAPITAL MANAGEMENT LP 1.98% STEMPOINT CAPITAL LP 1.3% Sio Capital Management, LLC 3Y 7Y 1.01% Ikarian Capital, LLC 3Y 0.97% PERCEPTIVE ADVISORS LLC 3Y 7Y 0.62% PLATINUM INVESTMENT MANAGEMENT LTD 3Y 7Y 0.39%
← Back to BRAIDWELL LP Holdings